News from avanir pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jul 21, 2014, 09:15 ET
Avanir Pharmaceuticals, Inc.  (PRNewsFoto/Avanir Pharmaceuticals, Inc.)

Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder

 Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. Food and Drug Administration (FDA) accepted the company's...

Jul 16, 2014, 09:00 ET
Avanir Pharmaceuticals, Inc.  (PRNewsFoto/Avanir Pharmaceuticals, Inc.)

Avanir Pharmaceuticals Announces Presentation of Positive Early Results from PRISM II Study

 Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced interim data from the phase IV PRISM II study showing that treatment with...

Jun 30, 2014, 19:22 ET
Avanir Pharmaceuticals, Inc.  (PRNewsFoto/Avanir Pharmaceuticals, Inc.)

Avanir Pharmaceuticals Announces Two Data Presentations Related to Pseudobulbar Affect (PBA) at the Alzheimer's Association International Conference (AAIC)

Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data related to pseudobulbar affect (PBA), a neurological condition characterized...

Jun 24, 2014, 08:30 ET
Avanir Pharmaceuticals, Inc.  (PRNewsFoto/Avanir Pharmaceuticals, Inc.)

Avanir Pharmaceuticals Announces Three Data Presentations Related to AVP-825 for the Acute Treatment of Migraine at the American Headache Society Annual Meeting

 Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data related to the safety and efficacy of AVP-825, a Breath-Powered™...

Jun 10, 2014, 04:00 ET
Avanir Pharmaceuticals, Inc.  (PRNewsFoto/Avanir Pharmaceuticals, Inc.)

Avanir Pharmaceuticals Announces Positive Outcome of Phase IIIb COMPASS Trial: A Head-to-Head Study Comparing AVP-825 to Oral Sumatriptan for the Acute Treatment of Migraine

 Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that COMPASS, its Phase IIIb clinical trial comparing the efficacy and safety of...

May 30, 2014, 09:00 ET
Avanir Pharmaceuticals, Inc.  (PRNewsFoto/Avanir Pharmaceuticals, Inc.)

Avanir Pharmaceuticals Announces Multiple Data Presentations Related to Pseudobulbar Affect (PBA) Prevalence and Treatment at Two Conferences in June

 Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data related to the prevalence and treatment of pseudobulbar affect (PBA), a...

May 28, 2014, 09:00 ET
Avanir Pharmaceuticals, Inc.  (PRNewsFoto/Avanir Pharmaceuticals, Inc.)

Avanir Pharmaceuticals to Participate in Two Conferences in June

Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the following...

May 27, 2014, 09:00 ET
Avanir Pharmaceuticals, Inc.  (PRNewsFoto/Avanir Pharmaceuticals, Inc.)

Avanir Pharmaceuticals Announces Completion of Patient Enrollment in Study of AVP-923 for the Treatment of Agitation in Patients with Alzheimer's Disease

 Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced completion of patient enrollment in the company's phase II, placebo controlled...

May 06, 2014, 16:01 ET
Avanir Pharmaceuticals, Inc.  (PRNewsFoto/Avanir Pharmaceuticals, Inc.)

Avanir Pharmaceuticals Reports Fiscal 2014 Second Quarter Financial and Business Results

 Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and six months ended March 31, 2014. Quarterly...

May 01, 2014, 16:00 ET
Avanir Pharmaceuticals, Inc.  (PRNewsFoto/Avanir Pharmaceuticals, Inc.)

Avanir Pharmaceuticals to Participate in Two Conferences in May

Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the following...

Apr 30, 2014, 15:04 ET
Avanir Pharmaceuticals, Inc.  (PRNewsFoto/Avanir Pharmaceuticals, Inc.)

Avanir Pharmaceuticals Prevails in NUEDEXTA Patent Trial Resulting in Exclusivity Through 2026

Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. District Court for the District of Delaware has ruled in favor of Avanir...

Apr 28, 2014, 08:30 ET
Avanir Pharmaceuticals, Inc.  (PRNewsFoto/Avanir Pharmaceuticals, Inc.)

Avanir Pharmaceuticals Announces Multiple Data Presentations Highlighting Its Central Nervous System (CNS) Therapeutics Franchise at the 66th Annual Meeting of the American Academy of Neurology

Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data from its CNS therapeutics franchise, specifically in its pseudobulbar affect...

Mar 26, 2014, 09:00 ET
Avanir Pharmaceuticals, Inc.  (PRNewsFoto/Avanir Pharmaceuticals, Inc.)

Avanir Pharmaceuticals Announces Acceptance of New Drug Application for AVP-825 for the Acute Treatment of Migraine

Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug...

Mar 20, 2014, 09:00 ET
Avanir Pharmaceuticals, Inc.  (PRNewsFoto/Avanir Pharmaceuticals, Inc.)

Avanir Pharmaceuticals Announces Publication of Research Showing Dextromethorphan has Antidepressant-like Effects In Vivo

Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the publication of data showing that dextromethorphan has antidepressant-like effects...

Mar 19, 2014, 16:00 ET
Avanir Pharmaceuticals, Inc.  (PRNewsFoto/Avanir Pharmaceuticals, Inc.)

Avanir Pharmaceuticals Announces Appointment of Mark Corrigan to Board of Directors

 Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the appointment of Dr. Mark Corrigan to the company's board of directors. Dr....

Mar 19, 2014, 09:40 ET
Avanir Pharmaceuticals, Inc.  (PRNewsFoto/Avanir Pharmaceuticals, Inc.)

Avanir Pharmaceuticals Presents Data from a Benchmark Study of PBA Symptoms in Veterans with Mild Traumatic Brain Injury

 Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the presentation of results from a first-of-its-kind study of pseudobulbar affect...

Feb 28, 2014, 09:00 ET
Avanir Pharmaceuticals, Inc.  (PRNewsFoto/Avanir Pharmaceuticals, Inc.)

Avanir Pharmaceuticals to Participate in Two Conferences in March

 Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the following...

Feb 07, 2014, 16:00 ET
Avanir Pharmaceuticals, Inc.  (PRNewsFoto/Avanir Pharmaceuticals, Inc.)

Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

 Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) Avanir announced that on February 4, 2014, the Company approved the grant of stock options to new...

Feb 05, 2014, 16:00 ET
Avanir Pharmaceuticals, Inc.  (PRNewsFoto/Avanir Pharmaceuticals, Inc.)

Avanir Pharmaceuticals Reports Fiscal 2014 First Quarter Financial And Business Results

Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three months ended December 31, 2013. Quarterly Financial...

Jan 30, 2014, 09:00 ET
Avanir Pharmaceuticals, Inc.  (PRNewsFoto/Avanir Pharmaceuticals, Inc.)

Avanir Pharmaceuticals Announces Submission of New Drug Application for AVP-825 for the Acute Treatment of Migraine

Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Investor-Edge